Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Her2+ • University of Utah
Would you use 6 months (instead of 12 months) of trastuzumab for locally advanced Her-2 positive breast cancer patients?
Would you do this for ER+ patients?
According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Herceptin is non-inferior to 12 months of trastuzumab. Subgroup analysis showed benefit in ER positive group.
Answer from: Medical Oncologist at Academic Institution
I would not recommend 6 months of maintenance trastuzumab for higher risk patients, such as one that received neoadjuvant therapy. The PERSEPHONE trial1 had as its strength its large size and sufficient number of events for a conclusion regarding the population tested (and the diversity of regimens...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
What would you consider as being low risk vs. high risk disease?
Answer from: Medical Oncologist at Academic Institution
I will not use 6 months of trastuzumab among patients with locally advanced breast cancer. As @Debu Tripathy stated, while the data from the PERSEPHONE trial presented at ASCO showed non-inferiority between 6 and 12 months, we should wait for the final peer-reviewed manuscript where more inform...